Price$4.47-6.40 (-58.85%)
2026-05-212026-08-25
News · 26 weeks55+350%
2026-03-012026-08-23
Mix3290d
- SEC Filings13(41%)
- Insider13(41%)
- Other4(13%)
- Offering2(6%)
Latest news
25 items- SECEdesa Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Edesa Biotech, Inc. (0001540159) (Filer)
- SECSEC Form 424B5 filed by Edesa Biotech Inc.424B5 - Edesa Biotech, Inc. (0001540159) (Filer)
- PREdesa Biotech Announces Pricing of $25.0 Million Public OfferingTORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA) (the "Company" or "Edesa"), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the pricing of an underwritten public offering consisting of (i) 3,870,500 common shares and accompanying common share warrants to purchase an aggregate of 3,870,500 common shares and (ii) in lieu of common shares to investors who so choose, pre-funded warrants to purchase up to 675,000 common shares and accompanying common share warrants to purchase an aggregate of 675,000 common shares, at an exercise price of $0.0001 per pre-funded warrant. Ea
- SECSEC Form 424B5 filed by Edesa Biotech Inc.424B5 - Edesa Biotech, Inc. (0001540159) (Filer)
- PREdesa Biotech Announces Proposed Public OfferingTORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA) (the "Company" or "Edesa"), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it has commenced an underwritten public offering of its common shares (or pre-funded warrants to purchase common shares in lieu thereof) and accompanying common share warrants to purchase common shares. In addition, Edesa expects to grant the underwriters a 30-day option to purchase additional common shares and accompanying common share warrants in an amount up to 15% of the total number of common shares (or pre-funded warrants in lieu thereo
- SECSEC Form 10-Q filed by Edesa Biotech Inc.10-Q - Edesa Biotech, Inc. (0001540159) (Filer)
- SECEdesa Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Edesa Biotech, Inc. (0001540159) (Filer)
- PREdesa Biotech Reports Fiscal 3rd Quarter 2026 ResultsTORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2026 and provided an update on its business. During the third quarter, Edesa completed preparations for its Phase 2 clinical study of EB06 (an anti-CXCL10 monoclonal antibody) in patients with moderate-to-severe nonsegmental vitiligo. Subsequent to quarter-end, the company began activating its first investigational sites and expects recruitment to begin in the coming weeks in Canada, with additional jurisdiction
- INSIDERChief Executive Officer Nijhawan Pardeep was granted 5,324 shares, increasing direct ownership by 0.60% to 893,386 units (SEC Form 4)4 - Edesa Biotech, Inc. (0001540159) (Issuer)
- SECSEC Form EFFECT filed by Edesa Biotech Inc.EFFECT - Edesa Biotech, Inc. (0001540159) (Filer)
- SECSEC Form 424B3 filed by Edesa Biotech Inc.424B3 - Edesa Biotech, Inc. (0001540159) (Filer)
- INSIDERChief Executive Officer Nijhawan Pardeep was granted 3,378 shares, increasing direct ownership by 0.38% to 888,062 units (SEC Form 4)4 - Edesa Biotech, Inc. (0001540159) (Issuer)
- SECSEC Form S-3 filed by Edesa Biotech Inc.S-3 - Edesa Biotech, Inc. (0001540159) (Filer)
- SECSEC Form D filed by Edesa Biotech Inc.D - Edesa Biotech, Inc. (0001540159) (Filer)
- SECSEC Form SCHEDULE 13G filed by Edesa Biotech Inc.SCHEDULE 13G - Edesa Biotech, Inc. (0001540159) (Subject)
- INSIDERChief Executive Officer Nijhawan Pardeep was granted 153,550 shares, increasing direct ownership by 21% to 884,684 units (SEC Form 4)4 - Edesa Biotech, Inc. (0001540159) (Issuer)
- SECEdesa Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Edesa Biotech, Inc. (0001540159) (Filer)
- PREdesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused InvestorsTORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA) (the "Company" or "Edesa"), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $3.5 million to the Company, before deducting offering expenses payable by Edesa. The common shares were placed without an agent, underwriter, broker or dealer. Investors in the PIPE include Edesa's Chief Executive Officer and healthcare-focused investors. The PIPE is ex
- SECEdesa Biotech Inc. filed SEC Form 8-K: Other Events8-K - Edesa Biotech, Inc. (0001540159) (Filer)
- PREdesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney InjuryAnalyses demonstrate consistent positive signals across endpoints in AKI patientsFindings derived from post hoc analysis of 101 patients also experiencing respiratory distressNew data and analysis to be presented today at the 63rd European Renal Association Congress TORONTO, June 05, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today reported favorable exploratory data for paridiprubart, its first-in-class anti-TLR4 monoclonal antibody, in patients with acute kidney injury (AKI) and respiratory distress. The data, which expand upon previously reported Phase 3
- INSIDERChief Executive Officer Nijhawan Pardeep was granted 1,671 shares, increasing direct ownership by 0.23% to 731,134 units (SEC Form 4)4 - Edesa Biotech, Inc. (0001540159) (Issuer)
- INSIDERDirector Marshall Patrick was granted 19,000 shares, increasing direct ownership by 36% to 71,666 units (SEC Form 4)4 - Edesa Biotech, Inc. (0001540159) (Issuer)
- INSIDERDirector Macdonald Sean Arthur was granted 19,000 shares, increasing direct ownership by 86% to 41,054 units (SEC Form 4)4 - Edesa Biotech, Inc. (0001540159) (Issuer)
- INSIDERDirector Chypyha Joan was granted 19,000 shares, increasing direct ownership by 172% to 30,029 units (SEC Form 4)4 - Edesa Biotech, Inc. (0001540159) (Issuer)
- INSIDERChief Financial Officer Weiler Peter J. was granted 64,609 shares, increasing direct ownership by 99% to 129,609 units (SEC Form 4)4 - Edesa Biotech, Inc. (0001540159) (Issuer)
EDSA FAQ
6 questionsWhat does Edesa Biotech Inc. do?
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an...Where does EDSA stock trade?
Edesa Biotech Inc. (EDSA) is listed on NASDAQ.What sector and industry is EDSA in?
Edesa Biotech Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about EDSA?
Edesa Biotech Inc. has had 1 recent analyst action on file. The most recent action was from HC Wainwright & Co.: Buy with a $1600.00 price target on 2021-12-20. Recent price targets cluster around $1600.00.What companies are similar to EDSA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare EDSA side-by-side with any of them on Quantisnow.How can I track EDSA on Quantisnow?
Quantisnow aggregates Edesa Biotech Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EDSA to receive live email and push alerts on every new disclosure.